The European Medicines Agency (EMEA) has recommended the approval of Thalidomide Pharmion (thalidomide) for the treatment of multiple myeloma.
Meeting on 21-24 January 2008, the Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Thalidomide Pharmion in combination with melphalan and prednisone outweigh its risks for the first-line treatment of multiple myeloma for patients over 65 years of age or who cannot be treated with high-dose chemotherapy.